11/29
01:34 am
acrv
H.C. Wainwright Initiates Coverage on Acrivon Therapeutics (ACRV) With “Buy” Rating and $19 PT [Yahoo! Finance]
Low
Report
H.C. Wainwright Initiates Coverage on Acrivon Therapeutics (ACRV) With “Buy” Rating and $19 PT [Yahoo! Finance]
11/25
08:07 am
acrv
Acrivon Therapeutics (NASDAQ:ACRV) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
Low
Report
Acrivon Therapeutics (NASDAQ:ACRV) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
11/22
02:11 am
acrv
Acrivon Therapeutics (NASDAQ:ACRV) was upgraded by analysts at
Wall Stre
Low
Report
Acrivon Therapeutics (NASDAQ:ACRV) was upgraded by analysts at
Wall Stre
11/22
02:11 am
acrv
Acrivon Therapeutics (NASDAQ:ACRV) was upgraded by analysts at
Wall Stre
Low
Report
Acrivon Therapeutics (NASDAQ:ACRV) was upgraded by analysts at
Wall Stre
10/22
05:23 pm
acrv
Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference [Yahoo! Finance]
Low
Report
Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference [Yahoo! Finance]
10/22
04:15 pm
acrv
Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference
Low
Report
Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference
10/3
02:37 pm
acrv
Acrivon Therapeutics (NASDAQ:ACRV) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Acrivon Therapeutics (NASDAQ:ACRV) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
10/1
04:51 pm
acrv
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
10/1
04:30 pm
acrv
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)